Competition is tightening, with Eli Lilly (NYSE:LLY) racing alongside Novo in the GLP-1 space. Novo's pipeline powerhouse, CagriSema, recently fell short of its weight-loss goals, but its established ...
Ascentage aims to raise $149 mln via US IPO Plans to offer 7.3 mln American depositary shares at $20.34 each Company's shares already listed in Hong Kong Jan 21 (Reuters) - Ascentage Pharma (6855 ...
The pressure on Novo Nordisk redoubled in December 2024. The results of a phase III clinical trial — an advanced stage of research — for its experimental drug CagriSema set off alarm bells: patients ...
Novo is already licking its wounds from another setbackits experimental two-drug combo, CagriSema, underwhelmed in trials, landing at 22.7% weight loss, barely moving the needle against Zepbound. With ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...
Former Justice H S Bhalla has taken on the role of administrator for the Haryana Olympic Association, marking a significant transition for sports in the state. An HOA representative confirmed that ...
A big catalyst for the stock could come in June when the company is expected to provide more detailed clinical results for CagriSema, its next-generation weight loss drug. Investors were ...
If we had written this article a couple of months back, Novo’s obesity drug CagriSema would have been a serious candidate for the list. However, the clinical trial results disappointed and even caused ...
Last month, Novo Nordisk announced disappointing data from a late-stage study on its next-generation obesity drug, CagriSema. Shares of NVO declined 4% on Tuesday, while VKTX was down 12.7% after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results